Pharmacogenomics Corner

Back to articles

Pharmacogenetic-guided clozapine monitoring decisions shown to be cost effective

KEY POINT

Genotype-guided blood sampling before clozapine initiation to guide monitoring decisions in patients with increased susceptibility to clozapine-induced agranulocytosis was shown to be cost effective, according to results of a pharmacoeconomic analysis published in The Pharmacogenomics Journal.

SOURCES

Girardin FR, et al. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2018;[Epub ahead of print].

de With SAJ, et al. More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J. 2017;17(4):304–11.